Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily
| Autor: | Peter Bolli, Rudolf Ritz, Müller Fb, P. Frei, Fritz R. Bühler, L. Glaus, G. L. Cooper, L. F. Allsopp |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1985 |
| Předmět: |
Adult
Male Supine position Physical Exertion Diastole Blood Pressure Placebo Essential hypertension Heart Rate Heart rate Medicine Humans Pharmacology (medical) Dosing cardiovascular diseases Aged Pharmacology business.industry Oxprenolol Middle Aged medicine.disease Blood pressure Anesthesia Delayed-Action Preparations Hypertension Female business Oxprenolol Oros Studies medicine.drug circulatory and respiratory physiology |
| Popis: | Nineteen patients receiving oxprenolol slow-release (SR) 160 mg (three patients) or 320 mg (16 patients) once daily for mild to moderate hypertension were treated with oxprenolol Oros 16/260 once daily for 3 weeks following a 2 week placebo wash-out period. Repeated dosing with both Oros and SR oxprenolol preparations, in comparison with placebo, significantly reduced supine systolic and diastolic blood pressures, and pulse rate at 24 h after dosing. Single Oros doses also significantly reduced pulse rate and diastolic, but not systolic, blood pressure at 24 h. The reduction in supine systolic blood pressure was greater during repeated dosing with oxprenolol SR than after a single dose of the Oros preparation. Control of supine diastolic blood pressure (less than or equal to 90 mm Hg) at 24 h after dosing was achieved in 13 out of 18 patients with oxprenolol SR (two out of three patients given 160 mg, and 11 out of 15 given 320 mg). Similar control was achieved in 11 out of 18 patients after a single dose of oxprenolol Oros, and in 13 out of 17 patients treated for 3 weeks. The mean percentage reduction in exercise heart rate (EHR) compared to placebo, at 24 h after dosing, was 16% following Oros treatment for 3 weeks, and 12% following SR administration. After a single dose of oxprenolol Oros EHR, was reduced by 9% at 24 h compared to placebo. At 3 weeks the Oros formulation was significantly better than the SR tablet at reducing EHR. Oxprenolol Oros 16/260 was effective over 24 h and well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|